Previous studies have adequately demonstrated that ER-positive/ERBB2-positive breast cancer models simulate clinical cases by exhibiting TAM-resistance relative to TAM-sensitive ER-positive/ERBB2-negative models and cases [18,32,33]. This evidence concerns the gene ESR1 and breast cancer.